Morning Analyst Calls Briefing for Tuesday, November 1, 2022
Here are more research calls issued early Wednesday morning.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
This report was sent to Briefing.com subscribers earlier today.
Upgrades:
> BioCryst Pharma (BCRX) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $16
> Danske Bank A/S (DNKEY) upgraded to Buy from Hold at Deutsche Bank
> Denali Therapeutics (DNLI) upgraded to Buy from Neutral at BTIG Research; tgt $38
> KKR (KKR) upgraded to Buy from Neutral at BofA Securities; tgt raised to $60
> Premier (PINC) upgraded to Outperform from Neutral at Robert W. Baird; tgt $41
Downgrades:
> Avista (AVA) downgraded to Neutral from Buy at Mizuho; tgt lowered to $40
> Blueprint Medicines (BPMC) downgraded to Perform from Outperform at Oppenheimer
> Catalent (CTLT) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $60
> Iberdrola SA (IBDRY) downgraded to Equal-Weight from Overweight at Morgan Stanley
> Ocado (OCDGF) downgraded to Underweight from Neutral at JP Morgan
> SeaSpine (SPNE) downgraded to Hold from Buy at Truist; tgt lowered to $6.75
> Twilio (TWLO) downgraded to Underperform from Buy at BofA Securities; tgt lowered to $85
Others:
> Cronos Group (CRON) initiated with a Mkt Perform at Bernstein; tgt $3
> Denali Therapeutics (DNLI) initiated with a Buy at BofA Securities; tgt $40
> OneSpaWorld (OSW) initiated with a Buy at Truist; tgt $12
> Tilray (TLRY) initiated with a Mkt Perform at Bernstein; tgt $3.90
Research calls posted earlier this morning are available here.
Contact [email protected] for any questions or corrections.